NYSE:BIO

Bio-Rad Laboratories Competitors

$602.57
+10.34 (+1.75 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$593.53
Now: $602.57
$602.85
50-Day Range
$554.11
MA: $579.59
$651.50
52-Week Range
$390.93
Now: $602.57
$689.00
Volume125,800 shs
Average Volume217,307 shs
Market Capitalization$17.98 billion
P/E Ratio5.16
Dividend YieldN/A
Beta0.83

Competitors

Bio-Rad Laboratories (NYSE:BIO) Vs. TMO, ILMN, A, MTD, WAT, and TECH

Should you be buying BIO stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to Bio-Rad Laboratories, including Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), and Bio-Techne (TECH).

Thermo Fisher Scientific (NYSE:TMO) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.

Valuation and Earnings

This table compares Thermo Fisher Scientific and Bio-Rad Laboratories' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$25.54 billion7.38$3.70 billion$12.3538.78
Bio-Rad Laboratories$2.31 billion7.78$1.76 billion$7.0685.35

Thermo Fisher Scientific has higher revenue and earnings than Bio-Rad Laboratories. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Thermo Fisher Scientific and Bio-Rad Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thermo Fisher Scientific031702.85
Bio-Rad Laboratories00303.00

Thermo Fisher Scientific currently has a consensus price target of $526.3684, indicating a potential upside of 9.92%. Bio-Rad Laboratories has a consensus price target of $700.00, indicating a potential upside of 16.17%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Thermo Fisher Scientific.

Volatility & Risk

Thermo Fisher Scientific has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares Thermo Fisher Scientific and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thermo Fisher Scientific17.12%21.35%10.55%
Bio-Rad Laboratories147.91%3.77%2.74%

Insider and Institutional Ownership

87.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 63.0% of Bio-Rad Laboratories shares are owned by institutional investors. 0.4% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Thermo Fisher Scientific beats Bio-Rad Laboratories on 9 of the 14 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Illumina (NASDAQ:ILMN) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Institutional and Insider Ownership

63.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 27.5% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 0.4% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Bio-Rad Laboratories has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.

Profitability

This table compares Bio-Rad Laboratories and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories147.91%3.77%2.74%
Illumina19.70%15.93%10.09%

Earnings and Valuation

This table compares Bio-Rad Laboratories and Illumina's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion7.78$1.76 billion$7.0685.35
Illumina$3.54 billion16.61$1.00 billion$6.5761.40

Bio-Rad Laboratories has higher earnings, but lower revenue than Illumina. Illumina is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Bio-Rad Laboratories and Illumina, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories00303.00
Illumina48602.11

Bio-Rad Laboratories currently has a consensus target price of $700.00, indicating a potential upside of 16.17%. Illumina has a consensus target price of $370.5789, indicating a potential downside of 8.13%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, equities research analysts plainly believe Bio-Rad Laboratories is more favorable than Illumina.

Summary

Illumina beats Bio-Rad Laboratories on 8 of the 14 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Insider & Institutional Ownership

63.0% of Bio-Rad Laboratories shares are owned by institutional investors. 27.5% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Agilent Technologies has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares Agilent Technologies and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agilent Technologies13.47%21.02%10.73%
Bio-Rad Laboratories147.91%3.77%2.74%

Valuation & Earnings

This table compares Agilent Technologies and Bio-Rad Laboratories' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agilent Technologies$5.34 billion7.53$719 million$3.2840.22
Bio-Rad Laboratories$2.31 billion7.78$1.76 billion$7.0685.35

Bio-Rad Laboratories has lower revenue, but higher earnings than Agilent Technologies. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Agilent Technologies and Bio-Rad Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agilent Technologies081902.70
Bio-Rad Laboratories00303.00

Agilent Technologies currently has a consensus price target of $104.70, indicating a potential downside of 20.63%. Bio-Rad Laboratories has a consensus price target of $700.00, indicating a potential upside of 16.17%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Agilent Technologies.

Summary

Bio-Rad Laboratories beats Agilent Technologies on 8 of the 14 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Insider & Institutional Ownership

93.2% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 63.0% of Bio-Rad Laboratories shares are owned by institutional investors. 3.2% of Mettler-Toledo International shares are owned by company insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Mettler-Toledo International has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares Mettler-Toledo International and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mettler-Toledo International19.36%144.89%21.11%
Bio-Rad Laboratories147.91%3.77%2.74%

Valuation & Earnings

This table compares Mettler-Toledo International and Bio-Rad Laboratories' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$3.01 billion9.48$561.11 million$22.7753.69
Bio-Rad Laboratories$2.31 billion7.78$1.76 billion$7.0685.35

Bio-Rad Laboratories has lower revenue, but higher earnings than Mettler-Toledo International. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Mettler-Toledo International and Bio-Rad Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mettler-Toledo International35101.78
Bio-Rad Laboratories00303.00

Mettler-Toledo International currently has a consensus price target of $971.3750, indicating a potential downside of 20.54%. Bio-Rad Laboratories has a consensus price target of $700.00, indicating a potential upside of 16.17%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Mettler-Toledo International.

Summary

Mettler-Toledo International beats Bio-Rad Laboratories on 8 of the 14 factors compared between the two stocks.

Waters (NYSE:WAT) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Insider & Institutional Ownership

91.8% of Waters shares are owned by institutional investors. Comparatively, 63.0% of Bio-Rad Laboratories shares are owned by institutional investors. 1.5% of Waters shares are owned by company insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Waters has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares Waters and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Waters22.61%-349.31%21.11%
Bio-Rad Laboratories147.91%3.77%2.74%

Valuation & Earnings

This table compares Waters and Bio-Rad Laboratories' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$2.41 billion7.92$592.20 million$8.9934.16
Bio-Rad Laboratories$2.31 billion7.78$1.76 billion$7.0685.35

Bio-Rad Laboratories has lower revenue, but higher earnings than Waters. Waters is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Waters and Bio-Rad Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Waters48101.77
Bio-Rad Laboratories00303.00

Waters currently has a consensus price target of $224.20, indicating a potential downside of 27.00%. Bio-Rad Laboratories has a consensus price target of $700.00, indicating a potential upside of 16.17%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Waters.

Bio-Techne (NASDAQ:TECH) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Valuation & Earnings

This table compares Bio-Techne and Bio-Rad Laboratories' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$738.69 million21.47$229.30 million$3.86105.89
Bio-Rad Laboratories$2.31 billion7.78$1.76 billion$7.0685.35

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

93.8% of Bio-Techne shares are owned by institutional investors. Comparatively, 63.0% of Bio-Rad Laboratories shares are owned by institutional investors. 3.8% of Bio-Techne shares are owned by company insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Bio-Techne and Bio-Rad Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Techne03702.70
Bio-Rad Laboratories00303.00

Bio-Techne currently has a consensus price target of $367.50, indicating a potential downside of 10.09%. Bio-Rad Laboratories has a consensus price target of $700.00, indicating a potential upside of 16.17%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Techne.

Risk and Volatility

Bio-Techne has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares Bio-Techne and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Techne32.69%12.20%8.09%
Bio-Rad Laboratories147.91%3.77%2.74%


Bio-Rad Laboratories Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.1$478.88+1.5%$188.58 billion$25.54 billion39.25
Illumina logo
ILMN
Illumina
1.6$403.37+0.1%$58.85 billion$3.54 billion93.59
Agilent Technologies logo
A
Agilent Technologies
1.8$131.91+0.9%$40.19 billion$5.34 billion57.35
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,222.41+1.3%$28.51 billion$3.01 billion51.43
Waters logo
WAT
Waters
1.3$307.14+1.0%$19.06 billion$2.41 billion38.25
Bio-Techne logo
TECH
Bio-Techne
2.0$408.72+0.9%$15.86 billion$738.69 million65.40
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.3$306.40+0.4%$15.38 billion$2.62 billion51.07
PerkinElmer logo
PKI
PerkinElmer
1.9$133.39+1.4%$14.95 billion$2.88 billion36.25
Bruker logo
BRKR
Bruker
1.9$68.61+1.7%$10.40 billion$2.07 billion67.27
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$32.16+4.1%$6.21 billion$90.89 million-114.85
Luminex logo
LMNX
Luminex
1.8$32.95+2.0%$1.56 billion$334.64 million84.49
Fluidigm logo
FLDM
Fluidigm
1.8$4.60+2.4%$342.92 million$117.24 million-6.87
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.8$6.53+0.3%$260.06 million$116.18 million-36.28Analyst Downgrade
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$4.50+4.0%$72.05 million$420,000.00-1.69
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.